LANXESS Resultados de beneficios anteriores

Pasado controles de criterios 0/6

Los beneficios de LANXESS han disminuido a una tasa media anual de -66.4%, mientras que en la industria Chemicals los beneficios crecieron en un 9.6% anualmente. Los ingresos han ido creciendo a una tasa media de 2.1% al año.

Información clave

-66.4%

Tasa de crecimiento de los beneficios

-66.3%

Tasa de crecimiento del BPA

Crecimiento de la industria Chemicals	12.4%
Tasa de crecimiento de los ingresos	2.1%
Rentabilidad financiera	-15.7%
Margen neto	-10.9%
Última actualización de beneficios	30 Sep 2024

Actualizaciones de resultados anteriores recientes

Recent updates

Does LANXESS (ETR:LXS) Have A Healthy Balance Sheet?

Oct 30

Why We're Not Concerned About LANXESS Aktiengesellschaft's (ETR:LXS) Share Price

Sep 07

Is LANXESS (ETR:LXS) Using Debt Sensibly?

Jul 23

Is It Too Late To Consider Buying LANXESS Aktiengesellschaft (ETR:LXS)?

May 27

Why Investors Shouldn't Be Surprised By LANXESS Aktiengesellschaft's (ETR:LXS) P/S

May 08

Is There An Opportunity With LANXESS Aktiengesellschaft's (ETR:LXS) 42% Undervaluation?

Apr 20

LANXESS Aktiengesellschaft's (ETR:LXS) Intrinsic Value Is Potentially 28% Above Its Share Price

Apr 26

Is Now The Time To Look At Buying LANXESS Aktiengesellschaft (ETR:LXS)?

Feb 17

These 4 Measures Indicate That LANXESS (ETR:LXS) Is Using Debt Extensively

Jan 30

Is There An Opportunity With LANXESS Aktiengesellschaft's (ETR:LXS) 25% Undervaluation?

Jan 12

Is There Now An Opportunity In LANXESS Aktiengesellschaft (ETR:LXS)?

Nov 03

We Think LANXESS (ETR:LXS) Is Taking Some Risk With Its Debt

Oct 11

Is It Too Late To Consider Buying LANXESS Aktiengesellschaft (ETR:LXS)?

Aug 03

LANXESS (ETR:LXS) Has A Somewhat Strained Balance Sheet

Jul 11

LANXESS' (ETR:LXS) Dividend Will Be Increased To €1.05

May 09

LANXESS (ETR:LXS) Will Pay A Larger Dividend Than Last Year At €1.05

Apr 21

LANXESS' (ETR:LXS) Shareholders Will Receive A Bigger Dividend Than Last Year

Apr 04

LANXESS (ETR:LXS) Is Increasing Its Dividend To €1.05

Mar 13

At €53.00, Is It Time To Put LANXESS Aktiengesellschaft (ETR:LXS) On Your Watch List?

Feb 07

We Think LANXESS (ETR:LXS) Can Stay On Top Of Its Debt

Jan 17

At €59.04, Is It Time To Put LANXESS Aktiengesellschaft (ETR:LXS) On Your Watch List?

Oct 26

Desglose de ingresos y gastos

Cómo gana y gasta dinero LANXESS. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).

Historial de beneficios e ingresos

XTRA:LXS Ingresos, gastos y beneficios (EUR Millions)
Fecha	Ingresos	Beneficios	Gastos G+A	Gastos de I+D
30 Sep 24	6,319	-690	1,167	105
30 Jun 24	6,322	-822	1,164	102
31 Mar 24	6,422	-951	1,182	100
31 Dec 23	6,714	-843	1,238	99
30 Sep 23	7,251	-280	1,350	102
30 Jun 23	7,835	-65	1,438	104
31 Mar 23	8,056	128	1,439	105
31 Dec 22	8,088	184	1,398	102
30 Sep 22	7,794	191	1,330	100
30 Jun 22	7,190	147	1,229	99
31 Mar 22	6,660	146	1,171	96
31 Dec 21	6,101	116	1,107	95
30 Sep 21	5,925	119	1,050	99
30 Jun 21	5,805	105	1,018	100
31 Mar 21	5,772	863	1,022	105
31 Dec 20	6,104	892	1,056	108
30 Sep 20	6,237	883	1,088	110
30 Jun 20	6,480	938	1,110	113
31 Mar 20	6,768	231	1,127	113
31 Dec 19	6,802	255	1,115	114
30 Sep 19	6,559	266	1,055	105
30 Jun 19	6,641	243	1,066	106
31 Mar 19	6,746	212	1,072	106
31 Dec 18	6,824	190	1,084	109
30 Sep 18	7,066	144	1,166	110
30 Jun 18	6,990	138	1,167	109
31 Mar 18	6,873	63	1,165	110
31 Dec 17	6,530	23	1,111	103
30 Sep 17	6,810	73	1,103	116
30 Jun 17	7,021	83	1,087	121
31 Mar 17	7,252	166	1,072	124
31 Dec 16	7,699	192	1,116	131
30 Sep 16	7,590	205	1,092	128
30 Jun 16	7,622	184	1,093	126
31 Mar 16	7,784	196	1,097	128
31 Dec 15	7,902	165	1,078	130
30 Sep 15	8,000	82	1,060	134
30 Jun 15	8,087	76	1,048	141
31 Mar 15	8,001	44	1,039	147
31 Dec 14	8,006	47	1,052	160
30 Sep 14	8,116	-89	1,045	176
30 Jun 14	8,126	-113	1,059	180
31 Mar 14	8,248	-159	1,075	183
31 Dec 13	8,300	-159	1,083	186

Ingresos de calidad: LXS actualmente no es rentable.

Margen de beneficios creciente: LXS actualmente no es rentable.

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: LXS no es rentable, y las pérdidas han aumentado en los últimos 5 años a un ritmo de 66.4% al año.

Acelerando crecimiento: No se puede comparar el crecimiento de los beneficios de LXS en el último año con su promedio de 5 años, ya que actualmente no es rentable.

Beneficios vs. Industria: LXS no es rentable, por lo que resulta difícil comparar el crecimiento de sus beneficios en el último año con el de la industria Chemicals (5%).

Rentabilidad financiera

Alta ROE: LXS tiene una rentabilidad financiera negativa (-15.71%), ya que actualmente no es rentable.

LANXESS Resultados de beneficios anteriores

Pasado controles de criterios 0/6

Información clave

Actualizaciones de resultados anteriores recientes

Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Second quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

First quarter 2024 earnings released: €1.13 loss per share (vs €0.12 profit in 1Q 2023)

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

LANXESS Aktiengesellschaft to Report Q2, 2024 Results on Aug 09, 2024

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Recent updates

Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Does LANXESS (ETR:LXS) Have A Healthy Balance Sheet?

Consensus EPS estimates upgraded to €2.09 loss

UBE Corporation (TSE:4208) signed a contract to acquire Urethane Systems Business of LANXESS Aktiengesellschaft (XTRA:LXS) for an enterprise value of €460 million.

Why We're Not Concerned About LANXESS Aktiengesellschaft's (ETR:LXS) Share Price

Second quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Is LANXESS (ETR:LXS) Using Debt Sensibly?

Consensus EPS estimates fall by 11%

LANXESS Aktiengesellschaft Announces Executive Changes

Consensus EPS estimates fall by 11%

Is It Too Late To Consider Buying LANXESS Aktiengesellschaft (ETR:LXS)?

Upcoming dividend of €0.10 per share

Consensus EPS estimates fall by 11%

First quarter 2024 earnings released: €1.13 loss per share (vs €0.12 profit in 1Q 2023)

Why Investors Shouldn't Be Surprised By LANXESS Aktiengesellschaft's (ETR:LXS) P/S

Is There An Opportunity With LANXESS Aktiengesellschaft's (ETR:LXS) 42% Undervaluation?

Dividend reduced to €0.10

Consensus EPS estimates fall by 10%

Is LANXESS (ETR:LXS) Weighed On By Its Debt Load?

Consensus EPS estimates upgraded to €1.61 loss, revenue downgraded

What You Can Learn From LANXESS Aktiengesellschaft's (ETR:LXS) P/S

Lanxess Reportedly Seeks to Sell Polyurethane Ops

Price target decreased by 8.6% to €29.08

Is LANXESS (ETR:LXS) Using Too Much Debt?

New major risk - Revenue and earnings growth

New major risk - Revenue and earnings growth

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

LANXESS Aktiengesellschaft Proposes Dividend for the Fiscal Year 2023

A Look At The Fair Value Of LANXESS Aktiengesellschaft (ETR:LXS)

LANXESS Aktiengesellschaft to Report Q2, 2024 Results on Aug 09, 2024

Price target decreased by 9.1% to €33.45

Price target decreased by 7.2% to €34.82

LANXESS Aktiengesellschaft(XTRA:LXS) dropped from FTSE All-World Index (USD)

New major risk - Revenue and earnings growth

When Should You Buy LANXESS Aktiengesellschaft (ETR:LXS)?

These 4 Measures Indicate That LANXESS (ETR:LXS) Is Using Debt In A Risky Way

New major risk - Dividend sustainability

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Calculating The Fair Value Of LANXESS Aktiengesellschaft (ETR:LXS)

Consensus EPS estimates fall by 48%

Consensus EPS estimates fall by 88%

Price target decreased by 12% to €43.70

Investor sentiment deteriorates as stock falls 20%

When Should You Buy LANXESS Aktiengesellschaft (ETR:LXS)?

Upcoming dividend of €1.05 per share at 3.0% yield

Is LANXESS (ETR:LXS) A Risky Investment?

First quarter 2023 earnings released: EPS: €0.12 (vs €0.76 in 1Q 2022)

LANXESS Aktiengesellschaft's (ETR:LXS) Intrinsic Value Is Potentially 28% Above Its Share Price

Now 21% undervalued after recent price drop

Full year 2022 earnings: EPS misses analyst expectations

Consensus EPS estimates fall by 11%

Investor sentiment deteriorates as stock falls 19%

Is Now The Time To Look At Buying LANXESS Aktiengesellschaft (ETR:LXS)?

Now 20% undervalued

These 4 Measures Indicate That LANXESS (ETR:LXS) Is Using Debt Extensively

Now 22% undervalued

Is There An Opportunity With LANXESS Aktiengesellschaft's (ETR:LXS) 25% Undervaluation?

Investor sentiment improved over the past week

Third quarter 2022 earnings released: EPS: €0.97 (vs €0.46 in 3Q 2021)

Is There Now An Opportunity In LANXESS Aktiengesellschaft (ETR:LXS)?

We Think LANXESS (ETR:LXS) Is Taking Some Risk With Its Debt

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Is It Too Late To Consider Buying LANXESS Aktiengesellschaft (ETR:LXS)?

LANXESS (ETR:LXS) Has A Somewhat Strained Balance Sheet

LANXESS Aktiengesellschaft (XTRA:LXS) completed the acquisition of Microbial Control business unit of International Flavors & Fragrances Inc. (NYSE:IFF).

Investor sentiment deteriorated over the past week

LANXESS Aktiengesellschaft to Report Q3, 2023 Results on Nov 08, 2023

Advent International Corporation and LANXESS Aktiengesellschaft (XTRA:LXS) agreed to acquire Engineering Materials business of Royal DSM from Koninklijke DSM N.V. (ENXTAM:DSM) for €3.9 billion.

Investor sentiment improved over the past week